Refine by
Diabetes Type Articles & Analysis
132 news found
While primarily less soluble, Tirzepatide’s molecular complexity does not impede its significance in the study of type 2 diabetes and beyond. By facilitating explorations into multifaceted metabolic pathways, Tirzepatide enriches insights into dual receptor interactions that inspire the development of next-generation research models. ...
His research explored metabolic imbalances linked to Type 2 Diabetes, and he previously worked as a Research Engineer, focusing on NMR-based metabolic characterisation and magnetic homogeneity ...
Ace Therapeutics launches its cutting-edge in vivo models of diabetes mellitus. These models—chemically induced, genetically engineered, or diet-induced—have the potential to advance diabetes research by giving scientists the means to support the identification and development of novel treatment approaches. ...
Ace Therapeutics, a leading provider of preclinical research services and products, is proud to announce the launch of its extensive suite of diabetic mouse models. These models have been specifically designed to enable research on different types of diabetes including type 1, type 2, and gestational ...
This novel glucagon-like peptide-1 (GLP-1) receptor agonist has generated significant excitement within the pharmaceutical and life sciences industries due to its remarkable efficacy in managing type 2 diabetes. Semaglutide represents a paradigm shift in the treatment of type 2 diabetes, as it targets the root causes of the ...
Semaglutide Side Chain serves as a pivotal component in the synthesis of semaglutide, an innovative medication utilized in the treatment of type 2 diabetes. Huateng Pharma's unwavering dedication to excellence and innovation shines through in the meticulous development and production of these essential compounds, ensuring the highest standards of quality and ...
We are delighted to welcome Roczen to the community of healthcare organisations leveraging Vantage Software! We look forward to working together and helping them deliver exceptional care and support to those living with chronic conditions. Book a Free Demo ...
“Despite progress in risk reduction in type 2 diabetes, chronic kidney disease in type 1 diabetes remains understudied, leaving a huge unmet need to reduce the risks of end-stage kidney disease and cardiovascular events. ...
ByBayer AG
Alertgy plans to focus on non-invasive glucose monitoring of non-insulin dependent Type 2 diabetics and pre-diabetics during its FDA clinical trials. COVID Detection Alertgy’s patented RF sensor technology has the potential to detect molecules other than glucose, both inside the body and in lab-based settings. ...
ByAlertgy
About Chronic Kidney Disease in Type 2 Diabetes Chronic kidney disease (CKD) is a common and potentially deadly condition that is widely underrecognized. ...
ByBayer AG
Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as diabetic kidney disease (DKD), including diabetic nephropathy (DN), type 1 and type 2 diabetes (T1D / T2D), non-alcoholic steatohepatitis (NASH), complications of obesity and ...
“Patients with chronic kidney disease and type 2 diabetes are three times more likely to die from a cardiovascular event than those with type 2 diabetes alone. ...
ByBayer AG
(“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD). The Phase 2 trial of INV-202, a first-in-class, peripherally-acting CB1 inverse agonist, is a multi-centered, ...
An estimated 415 million people are living with diabetes in the world. Diabetes is a chronic disease, that causes blood sugar levels in your body to become too high, either due to your body not being able to respond properly to insulin or due to your body not being unable to produce any at all. If left untreated, this can lead to serious complications such as heart attack, stroke, obesity, eye ...
Over half of patients surveyed agreed that they consistently follow their healthcare providers’ recommendations for managing their diabetes. LifeScan, a world leader in blood glucose monitoring, today announced results of a new global research study, conducted by market research firm Burke, Inc., of 793 adults living with Type 2 ...
ByLifeScan
“Their cumulative experience with public and private biotech companies will be of great value to us as we advance our vision of serving patients suffering from Diabetic Kidney Diseases and Fibrosis with our new class of CB1 inverse agonists”, added Dr. ...
” The publication is entitled "Intralymphatic GAD-alum (Diamyd®) improves glycaemic control in Type 1 diabetes with HLA DR3-DQ2", and is expected to become freely accessible shortly in an Open Access version. ...
The diabetes vaccine Diamyd is uniquely well positioned to be studied for the prevention of clinical type 1 diabetes considering its strong safety profile and clinical efficacy in recent-onset type 1 diabetes”. ...
The last patient in the investigator-initiated clinical trial DIAGNODE-B has received its additional injection (“booster”) of the therapeutic diabetes vaccine Diamyd®. The trial includes 6 patients with Type 1 diabetes who earlier participated in the DIAGNODE-1 or DIAGNODE-2 trials and who carry the genetic HLA DR3-DQ2 haplotype. ...
Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity and ...